TY - JOUR
T1 - High Absolute Monocyte Count Predicts Poor Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel Chemotherapy
AU - Shigeta, Keisuke
AU - Kosaka, Takeo
AU - Kitano, Shigehisa
AU - Yasumizu, Yota
AU - Miyazaki, Yasumasa
AU - Mizuno, Ryuichi
AU - Shinojima, Toshiaki
AU - Kikuchi, Eiji
AU - Miyajima, Akira
AU - Tanoguchi, Hitoshi
AU - Hasegawa, Shintaro
AU - Oya, Mototsugu
PY - 2016/6/30
Y1 - 2016/6/30
N2 - Background: The association of peripheral monocyte count and prostate cancer progression is not well characterized. Objective: Our aim was to investigate the prognostic value of absolute monocyte count (AMC), which is thought to modulate immune response in the tumor microenvironment, in castration-resistant prostate cancer (CRPC) patients treated with docetaxel chemotherapy. Methods: We retrospectively reviewed the medical records of 214 CRPC patients who received docetaxel therapy and were used as the training and validation set. Docetaxel at a dose of 75 mg/m2 was administered every 3 or 4 weeks. Clinicopathological factors and laboratory data were collected to assess the prognostic factors for overall survival (OS) and progression-free survival (PFS). Results: In the training set, the median age was 73.0 years, and the median prostate-specific antigen (PSA) value was 31.7 ng/ml at initial treatment. The median OS and PFS were 23.0 months (range 1.20–84.0) and 11.2 months (range 3.6–78.0), respectively. According to multivariable Cox regression analysis, AMC ≥400/uL, PSA level ≥20 ng/ml, and Hb
AB - Background: The association of peripheral monocyte count and prostate cancer progression is not well characterized. Objective: Our aim was to investigate the prognostic value of absolute monocyte count (AMC), which is thought to modulate immune response in the tumor microenvironment, in castration-resistant prostate cancer (CRPC) patients treated with docetaxel chemotherapy. Methods: We retrospectively reviewed the medical records of 214 CRPC patients who received docetaxel therapy and were used as the training and validation set. Docetaxel at a dose of 75 mg/m2 was administered every 3 or 4 weeks. Clinicopathological factors and laboratory data were collected to assess the prognostic factors for overall survival (OS) and progression-free survival (PFS). Results: In the training set, the median age was 73.0 years, and the median prostate-specific antigen (PSA) value was 31.7 ng/ml at initial treatment. The median OS and PFS were 23.0 months (range 1.20–84.0) and 11.2 months (range 3.6–78.0), respectively. According to multivariable Cox regression analysis, AMC ≥400/uL, PSA level ≥20 ng/ml, and Hb
UR - http://www.scopus.com/inward/record.url?scp=84976500598&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84976500598&partnerID=8YFLogxK
U2 - 10.1245/s10434-016-5354-5
DO - 10.1245/s10434-016-5354-5
M3 - Article
C2 - 27364499
AN - SCOPUS:84976500598
SP - 1
EP - 8
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
SN - 1068-9265
ER -